Moreover, inhibition of glutamate release via system Xc−, consisting of xCT (SLC7A11) and CD98 (SLC3A2, 4F2HC), profoundly decelerates the glioma phenotype in vivo [4], [12], [26], and in addition mitigates tumor-induced brain swelling [4] and tumor-induced seizures [13]. Here, SLC3A2 is linked to neoplasm.